Imaging Biomarkers in Diabetic Retinopathy
Downloads
Published
Keywords:
.Dimensions Badge
Issue
Section
License
Copyright (c) 2023 UP JOURNAL OF OPHTHALMOLOGY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
© Author, Open Access. This article is licensed under a CC Attribution 4.0 License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/byncsa/4.0/.
Diabetic retinopathy (DR) is one of the leading causes of vision loss globally.' Among patients with DR, diabetic macular edema (DME) is the leading cause of moderate visual loss. In the current era, imaging modalities [Optical coherence tomography (OCT), fundus auto fluorescence (FAF), OCT angiography (OCT-A) and fluorescein angiography (FFA)] play an important role in deciding the treatment protocol as well as prognosticating outcome. This article will provide comprehensive summary of clinical applicability of OCTA derived quantitative metrics that appear to be clinically relevant to the diagnosis, classification, and management of patients with diabetes or DR.Abstract
How to Cite
Downloads
